NHS patients living with a genetic blood disorder are set to benefit from a gene-editing treatment which offers hope of a cure. The one-off gene therapy, Casgevy, has been approved for use on the NHS in England, by the National Institute for Health and Care Excellence (NICE) for older children and adults with a severe form of thalassaemia.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
